Final Program

28 SUNDAY • MAY 15
Chronic Cough: An Under Recognized Etiology
W. Warren, DO, Bethesda, MD
Progressive Dyspnea in a 40 Year Old Woman
H. Gaztambide, MD, Gainesville, FL
Lymphoproliferative Disorder: Diagnostic Considerations
V. Murthy, MD, New York, NY
A Diagnostic Dilemma: Waxing and Waning Pulmonary
Nodules
K. Treger, DO, Jacksonville, FL
10:10 Expert Discussants
A4
Expert Clinicians
M.I. Schwarz, MD, Aurora, CO
A.H. Limper, MD, Rochester, MN
P.E. Parsons, MD, Burlington, VT
Expert Pathologist
H.D. Tazelaar, MD, Scottsdale, AZ
Expert Radiologist
B.M. Elicker, MD, San Francisco, CA
CLINICAL
CRITICAL CARE TRACK
CME Credits Available: 2.0
NEW ERA OF EVIDENCE GENERATION:
MEASURING EFFECTIVENESS IN CRITICAL CARE
Assemblies on Critical Care; Clinical Problems; Nursing
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 3000/3002/3004 (West Building, Level 3)
Target Audience
Critical care providers; intensivists; nurse practitioners; quality improvement
researchers; hospital administrators; ICU administrators.
Objectives
At the conclusion of this session, the participant will be able to:
• understand novel trial design aspects of comparative effectiveness
research in critically ill patients and how the ICU can be a learning health
care system;
• interpret and apply the results of large effectiveness trials done in critically
ill patients;
• understand the ethics of comparative effectiveness research and issues of
consent.
Clinical trials using pragmatic design principles aimed at truly testing
effectiveness of process of care aspects or currently used treatments are
becoming increasingly popular. Federal funding, including both the NIH and
PCORI, have emphasized the need for these types of trials. Comparative
effectiveness and pragmatic trials conducted in the ICU are an emerging field in
both clinical and quality improvement research. This session will discuss the
increasing use of novel trial designs to generate estimates of treatment
effectiveness in the critically ill and how to interpret and apply the results of
these types of ICU studies.
Chairing: T.W. Rice, MD, MSc, Nashville, TN
D. Janz, MD, MSc, New Orleans, LA
9:00 What’s Pragmatic about Pragmatic Trials?
T.W. Rice, MD, MSc, Nashville, TN
9:10 Patient Centered Outcomes and Other Endpoints in Practical
ICU Studies
D. Janz, MD, MSc, New Orleans, LA
9:25 Unique Trial Designs: Recent Novel Pragmatic Trials in
Critical Illness
M.W. Semler, MD, Nashville, TN
9:40 Interpreting ICU Effectiveness Trials: Are the Results
Applicable to My ICU or Patients?
B.T. Thompson, MD, Boston, MA
10:00 To Ask or Not To Ask? Ethics, Informed Consent, and Stopping
Rules in Comparative Effectiveness Trials in Critical Illness
B. Cuthbertson, MD, Toronto, Canada
10:20 Fusing RCTs with Big Data in Critical Illness
D.C. Angus, MD, MPH, Pittsburgh, PA
10:40 The ICU as a Learning Healthcare Environment
J.V. Selby, MD, MPH, Washington, DC
A5
BASIC • CLINICAL • TRANSLATIONAL
BASIC SCIENCE CORE
CME Credits Available: 2.0
UNDERSTANDING LUNG DISEASE PHENOTYPES:
NETWORKS AND SYSTEMS BIOLOGY
Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell
and Molecular Biology; Respiratory Structure and Function
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2009/2011 (West Building, Level 2)
Target Audience
Basic and clinical scientists, research and clinical trainees, drug discovery and
development sector workers, providers of lung health care.
Objectives
At the conclusion of this session, the participant will be able to:
• understand fundamental approaches for systems biology and their
application in research of pathophysiology;
• become aware of approaches to study epigenetic, transcriptional, post
translational mechanism that contribute to lung diseases;
• learn new findings about post-transcriptional gene regulation.
The session highlights the state of the art in high throughput technologies and
bioinformatics relevant to a broad range of lung disorders. How advanced
bioinformatics can be used to understand integration of complex responses will
be discussed, focusing on how to understand complexities of cell signaling
disease pathogenesis.
Chairing: A.J. Ammit, PhD, Sydney, Australia
A. Fedulov, MD, PhD, Boston, MA
9:00 Asthma Is a Systemic Epigenetic Disease
R.L. Miller, MD, New York, NY
ATS 2016 • San Francisco